India Makes Major Push To Stem Increase In MDR-TB Risk
This article was originally published in PharmAsia News
Executive Summary
India plans to provide diagnostics equipment and treatments in an effort to meet a target of getting control by 2010 of multi-drug resistant tuberculosis in the country. The TB type is resistant to isoniazid and rifampicin, the best first-line drugs for fighting the disease. The rate of MDR-TB cases in India is not necessarily increasing any faster than in other developing countries, but is considered more troublesome in the country because of its huge population. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.